文章核心观点 SeaStar Medical宣布公开发行股票及认股权证，预计募资约400万美元，行使短期认股权证或额外获400万美元，资金用于一般公司用途 [1][4] 公司公开发行情况 - 公开发行6,153,847股普通股或预融资认股权证，同时发售A类和B类认股权证，组合发行价0.65美元/股 [1] - A类认股权证行使价0.65美元/股，发行后可行使，5年后到期；B类短期认股权证行使价0.65美元/股，发行后可行使，18个月后到期 [2] - 发行预计6月23日左右完成，需满足惯例成交条件 [2] - H.C. Wainwright & Co.担任独家配售代理 [3] - 发行总收益预计约400万美元，行使B类短期认股权证或额外获400万美元，公司拟将净收益用于一般公司用途 [4] - 证券发售依据6月16日提交、6月20日生效的S - 1注册声明，仅通过招股说明书进行发售 [5] 公司介绍 - SeaStar Medical是商业阶段医疗公司，专注改变器官衰竭和生命垂危重症患者治疗方式 [1][7] - 首款商业产品QUELIMMUNE (SCD - PED) 2024年获FDA批准，是唯一获批用于危重症儿科患者因败血症或脓毒症导致的危及生命的急性肾损伤的产品 [7] - 选择性细胞清除装置 (SCD) 疗法获FDA六项治疗适应症的突破性设备认定，公司正针对需持续肾脏替代疗法的成年急性肾损伤患者进行关键试验 [7] 联系方式 - 如需更多信息可访问www.seastarmedical.com或在LinkedIn、X上联系公司 [8] - 联系邮箱为IR@SEASTARMED.COM [11]

文章核心观点 美国国防部授予自主复苏与撤离（AREVA）研究所一笔超200万美元的赠款，支持其开展为期三年的研究，探索SeaStar Medical公司的选择性细胞清除设备（SCD）疗法在严重烧伤、吸入性损伤和败血症等情况下减少炎症的应用，有望推动体外免疫调节发展，改善患者预后 [1][2] 研究项目相关 - 赠款由2024年军事烧伤研究计划（MBRP）从160份提交项目中选出的四个项目之一，代表体外免疫调节前沿研究 [1] - 研究将于2025年7月开始，探索SCD疗法减少战士严重烧伤、吸入性损伤和感染后过度炎症的应用，或提高战斗伤员和平民患者生存率，减少透析需求 [2] - AREVA研究所负责人称此次合作可能拯救大量感染和创伤相关器官衰竭患者生命 [3] - SeaStar Medical首席医疗官表示该赠款是对AREVA研究所和SCD疗法的重大肯定，研究将评估SCD疗法优化损伤后功能恢复的能力 [4] SCD疗法介绍 - SCD疗法是一种疾病修饰设备，可中和过度活跃免疫细胞，阻止细胞因子风暴，有广泛应用，独特免疫调节方法或促进器官长期恢复，消除未来肾脏替代治疗需求，防止死亡 [5] 公司介绍 - SeaStar Medical是商业阶段医疗保健公司，首款商业产品QUELIMMUNE（SCD - PED）于2024年获FDA批准，是唯一获批用于小儿脓毒症急性肾损伤（AKI）的疗法，SCD疗法获FDA六项突破性设备认定，正处于成人AKI患者关键试验中 [6] 日内瓦基金会介绍 - 日内瓦基金会推进与国防部要求一致的军事相关研究，加速军事医学研发，提供可部署解决方案，增强军人及其服务社区的健康、准备状态和能力 [8]

Coverage marks SeaStar Medical’s second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a clinical trial Stands out as rare award with less than 100 clinical trials covered annually DENVER, May 28, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Centers for Medic ...

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  ICU Medical, Inc. (“ICU” or the “Company”) (NASDAQ: ICUI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether ICU and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 22, 2025, ICU ...

SeaStar Medical Holding (ICU) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Jackie Cossmon - ConsultantEric Schlorff - CEOTim Varacek - SVP - Commercial & Business OperationsKevin Chung - Chief Medical OfficerDavid Green - CFONicholas Sherwood - Equity Research Associate Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the SeaStar Medical First Quarter Financial Results Con ...

SeaStar Medical Holding (ICU) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the SeaStar Medical First Quarter Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Thank you. I would now like to turn the call over to Jackie K ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39927 SEASTAR MEDICAL HOLDING CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 85-3681132 (State or o ...

Exhibit 99.1 SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates DENVER, CO (May 14, 2025) – SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months ended March 31, 2025, and provided business updates on key initiatives. "This is our second full quarter of the QUELIMMUNE lau ...

QUELIMMUNE adoption drives four-fold increase in sequential quarter net revenue NEUTRALIZE AKI trial exceeds 50% enrollment, triggers start of Interim AnalysisWebcast Today at 4:30 pm Eastern Time DENVER, May 14, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months ended March 31, 2025 ...

Indication Has Been Granted FDA Breakthrough Device Designation for Potential PMA FilingDENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has successfully reached the halfway point in the NEUTRALIZE-AKI pivotal clinical trial, enabling a per protocol prespecified interim analysis by the trial’s ...